PODD [NASD]
Insulet Corporation
Index- P/E1322.67 EPS (ttm)0.22 Insider Own0.30% Shs Outstand69.42M Perf Week-1.09%
Market Cap20.10B Forward P/E266.46 EPS next Y1.10 Insider Trans-21.28% Shs Float69.12M Perf Month20.14%
Income16.80M PEG- EPS next Q0.21 Inst Own- Short Float / Ratio3.28% / 4.84 Perf Quarter10.82%
Sales1.24B P/S16.17 EPS this Y137.60% Inst Trans-0.62% Short Interest2.27M Perf Half Y24.28%
Book/sh6.17 P/B47.38 EPS next Y897.27% ROA0.80% Target Price309.25 Perf Year-1.04%
Cash/sh- P/C- EPS next 5Y- ROE3.60% 52W Range181.00 - 320.00 Perf YTD9.86%
Dividend- P/FCF- EPS past 5Y20.30% ROI4.40% 52W High-8.65% Beta0.77
Dividend %- Quick Ratio3.00 Sales past 5Y24.50% Gross Margin64.50% 52W Low61.50% ATR11.68
Employees2300 Current Ratio4.00 Sales Q/Q23.70% Oper. Margin5.10% RSI (14)57.68 Volatility2.12% 4.28%
OptionableYes Debt/Eq3.29 EPS Q/Q-141.40% Profit Margin1.40% Rel Volume0.50 Prev Close293.70
ShortableYes LT Debt/Eq3.22 EarningsNov 03 AMC Payout0.00% Avg Volume467.84K Price292.31
Recom2.10 SMA201.38% SMA5013.87% SMA20019.24% Volume237,879 Change-0.47%
Nov-04-22Upgrade Piper Sandler Neutral → Overweight $235 → $340
Oct-18-22Initiated Barclays Equal Weight $238
Oct-12-22Initiated Jefferies Hold $260
Jul-11-22Downgrade Citigroup Buy → Neutral $310 → $250
Mar-02-22Resumed BofA Securities Buy $300
Feb-03-22Upgrade BTIG Research Neutral → Buy $320
Feb-02-22Upgrade UBS Neutral → Buy $325
Jan-31-22Upgrade Oppenheimer Perform → Outperform $300 → $275
Jul-21-21Resumed Cowen Outperform $285 → $310
May-25-21Initiated Barclays Overweight $300
Show Previous Ratings
Nov-22-22 06:00AM
Nov-20-22 03:48PM
Nov-17-22 05:43PM
Nov-16-22 07:18AM
Nov-15-22 10:26AM
04:30PM Loading…
Nov-14-22 04:30PM
Nov-09-22 09:59AM
Nov-08-22 07:14AM
Nov-04-22 04:01PM
11:13AM
06:22AM
Nov-03-22 05:15PM
04:01PM
Nov-01-22 06:00AM
Oct-31-22 10:01AM
10:02AM Loading…
Oct-27-22 10:02AM
Oct-12-22 03:22PM
Sep-26-22 09:03AM
Sep-23-22 05:18PM
Sep-22-22 06:00AM
Sep-20-22 06:00AM
Sep-16-22 01:41PM
Sep-06-22 07:18AM
Sep-03-22 08:00AM
Aug-26-22 08:11AM
Aug-22-22 10:28AM
08:27AM
07:34AM
06:00AM
Aug-16-22 04:27PM
07:12AM Loading…
Aug-10-22 07:12AM
Aug-09-22 12:08PM
Aug-08-22 09:03AM
Aug-05-22 08:42AM
06:01AM
Aug-04-22 05:45PM
04:01PM
Aug-01-22 06:00AM
Jul-20-22 09:21AM
Jul-18-22 11:12AM
Jun-30-22 06:01AM
Jun-23-22 07:00AM
Jun-20-22 07:52AM
Jun-06-22 12:52PM
Jun-03-22 05:30PM
Jun-02-22 09:27AM
06:01AM
Jun-01-22 04:01PM
May-31-22 04:34PM
04:08PM
11:12AM
09:26AM
May-26-22 04:51PM
May-25-22 04:02PM
May-24-22 04:30PM
12:56PM
08:35AM
07:51AM
May-23-22 08:03PM
May-12-22 01:00PM
May-09-22 11:06AM
May-06-22 09:55AM
May-05-22 05:15PM
04:15PM
04:01PM
02:54PM
May-04-22 01:49PM
May-02-22 08:31AM
06:00AM
Apr-27-22 01:36PM
06:00AM
Apr-19-22 01:08AM
Apr-18-22 09:33AM
Apr-07-22 06:00AM
Mar-25-22 11:30AM
Mar-17-22 12:23PM
Mar-10-22 12:48PM
12:17PM
Mar-02-22 10:19AM
Feb-25-22 03:46PM
Feb-24-22 10:14AM
06:41AM
Feb-23-22 05:15PM
04:01PM
Feb-17-22 06:00AM
Feb-16-22 06:00AM
Feb-08-22 01:38PM
Feb-07-22 11:37AM
06:00AM
Feb-03-22 06:25PM
Feb-02-22 09:38AM
Jan-28-22 12:26PM
12:20PM
08:21AM
06:00AM
Jan-26-22 01:38PM
Jan-19-22 09:38AM
Jan-12-22 10:16AM
Jan-10-22 10:48AM
Dec-20-21 08:32AM
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Manea DanSVP, Chief HR OfficerNov 18Sale294.6220058,9243,158Nov 21 04:03 PM
Christensen BretEVP and CCONov 18Sale295.153,000885,45016,551Nov 21 04:02 PM
Spears Michael PSVP, RA and ComplianceNov 04Option Exercise46.226,290290,72422,450Nov 07 04:13 PM
Spears Michael PSVP, RA and ComplianceNov 04Sale308.9913,6584,220,1858,792Nov 07 04:13 PM
Petrovic ShaceyDirectorOct 03Option Exercise46.2215,000693,30028,695Oct 04 04:28 PM
Petrovic ShaceyDirectorOct 03Sale231.8015,0003,477,00013,695Oct 04 04:28 PM
Christensen BretEVP and CCOAug 24Sale264.242,900766,29619,551Aug 25 04:35 PM
Petrovic ShaceyDirectorJul 01Option Exercise38.2315,000573,39328,695Jul 06 04:17 PM
Petrovic ShaceyDirectorJul 01Sale222.9015,0003,343,50013,695Jul 06 04:17 PM
Alpuche CharlesEVP & Chief Operating OfficerJun 06Sale215.326,0001,291,92043,899Jun 07 04:50 PM
Petrovic ShaceyPresident and CEOApr 04Option Exercise29.2615,000438,90028,607Apr 05 04:17 PM
Petrovic ShaceyPresident and CEOApr 04Sale273.2515,0004,098,75013,607Apr 05 04:17 PM
McMillan Wayde D.EVP, CFOApr 01Sale275.601,455400,99821,354Apr 05 04:15 PM
Petrovic ShaceyPresident and CEOJan 05Option Exercise29.2615,000438,90032,249Jan 07 04:15 PM
Petrovic ShaceyPresident and CEOJan 05Sale264.9715,0003,974,55017,249Jan 07 04:15 PM
McMillan Wayde D.EVP, CFODec 31Sale268.981,855498,95620,078Jan 04 04:19 PM
Petrovic ShaceyPresident and CEODec 16Option Exercise46.222,16399,97417,942Dec 17 04:02 PM
Spears Michael PSVP, RA and ComplianceDec 06Option Exercise29.262,35068,76113,412Dec 08 04:38 PM